AROVELLA THERAPEUTICS LIMITED (ASX: ALA) — Company Overview, News & Financial Data
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer.
AROVELLA THERAPEUTICS LIMITED
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer. The company utilizes its proprietary CAR-iNKT cell therapy platform to create off-the-shelf, donor-derived therapeutics designed to target both blood cancers and solid tumors. Its lead research programs include CD19-targeted therapies for hematological malignancies and Claudin 18.2-targeted therapies for solid tumors such as gastric and pancreatic cancers. By combining chimeric antigen receptors with invariant T-cell receptor pathways and cytokine technology, the company develops multi-targeting cellular immunotherapies aimed at improving patient access and treatment outcomes.
Snapshot
Operations
Products and/or services of AROVELLA THERAPEUTICS LIMITED
- CD19-Targeting Cell Therapies: Development of allogeneic chimeric antigen receptor invariant Natural Killer T cell therapies directed against CD19 antigens for treating blood cancers, including non-Hodgkin lymphoma and B-cell leukemias in pediatric and adult patient populations.
- Claudin 18.2-Targeting Cell Therapies: Development of chimeric antigen receptor invariant Natural Killer T cell therapeutics engineered to target Claudin 18.2 expressers for the treatment of solid tumors, such as gastric and pancreatic cancers.
- Cytokine Enhancement Platform: Integration of membrane-anchored interleukin-12 cytokine technology into therapeutic cell constructs to improve cellular persistence, activation, and efficacy within immunosuppressive solid tumor microenvironments without systemic toxicity.
- Off-the-Shelf Allogeneic Cell Platform: Production of donor-derived invariant Natural Killer T cell therapies that do not induce graft-versus-host disease, providing scalable off-the-shelf cellular products for broader patient access compared to autologous treatments.
- CD1d-Mediated Dual-Targeting Platform: Utilization of invariant T-cell receptors to bind lipid antigens presented by CD1d molecules on tumor cells, enabling dual-action cancer targeting alongside chimeric antigen receptor mechanisms.
- Innate Cytotoxic Pathway Platform: Activation of natural killer cell receptor pathways, including NKG2D, to provide secondary tumor-killing capabilities and destroy immunosuppressive cells within the tumor microenvironment independent of targeted receptors.
AROVELLA THERAPEUTICS LIMITED executive team
- Nicole van der WeerdenActing Chief Executive Officer
- Lachie MalliaCFO & Company Secretary
- Michelle LongSenior Administration Manager
- Robson DossaSenior Vice President of Manufacturing & Quality
- Michelle FergusonSenior Director of Research & Development
Recent announcements
What AROVELLA THERAPEUTICS LIMITED (ALA) has told the market, newest first.
- Second Clinical Batch Released for Immediate Patient UsePrice sensitive
- Cell and Gene Innovation Spotlight Presentation
- Notice of Annual General Meeting/Proxy Form
- The path to first patient dosingPrice sensitive
Key financials
Reported results for AROVELLA THERAPEUTICS LIMITED, in AUD.
- Market cap
- 64.1M
- Revenue (TTM)
- 3.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -197.7%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -11.2M | -6.9M | |
| 136K | -11.2M | -7.5M | |
| 17K | -10.8M | -8.7M | |
| 405.9K | -9.7M | -10.2M |